DRMA: the cash flow

MyFinsight

Cash Flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total research and development	383,724	526,620	504,387	NaN
Total selling, general and administrative	1,542,658	1,373,773	3,469,842	NaN
Interest income	78,676	38,505	68,681	NaN
Net loss	-1,847,706	-1,861,888	-1,691,989	-4,004,680
Stock-based compensation	43,278	29,469	37,841	76,422
Prepaid expenses and other current assets	85,431	-65,435	247,697	-212,732
Inventory	93,091	NaN	NaN	NaN
Accounts payable	-51,128	-83,967	52,727	-356,816
Accrued and other current liabilities	-445,640	521,754	45,303	-552,205
Total adjustments to reconcile net loss to net cash used in operations	NaN	NaN	-111,826	-619,867
Net cash used in operating activities	-2,479,718	-1,329,197	-1,803,815	-4,624,547
Proceeds from exercise of pre-funded warrants	NaN	0	0	977
Proceeds from issuance of common stock, pre-funded warrants, and warrants, net of issuance costs	NaN	4,187,048	-12,621	7,993,425
Proceeds from issuance of common stock from atm sales, net of issuance costs	1,994,374	NaN	NaN	NaN
Payment of issuance costs	91,352	0	0	50,495
Issuance costs paid setting up atm agreement	NaN	NaN	NaN	0
Payment for fractional shares in reverse stock split	NaN	0	-367	0
Net cash provided by financing activities	1,903,022	4,187,048	-12,988	7,943,907
Net increase (decrease) in cash and cash equivalents	-576,696	2,857,851	-1,816,803	3,319,360
Cash and cash equivalents at beginning of period	7,521,978	4,664,127	3,161,570	NaN
Cash and cash equivalents at end of period	6,945,282	7,521,978	4,664,127	NaN

Unit: Dollar. Numbers labeled with * are estimated quarterly values.